Eli Lilly to Present New Data on Imlunestrant, Olomorasib, LY4170156, and Verzenio® at 2025 ASCO Annual Meeting Eli Lilly and Company (NYSE: LLY) announced today that new clinical data from its oncology pipeline—including imlunestrant, olomorasib, LY4170156, and Verzenio® (abemaciclib)—will be…
New data from SEQUOIA, to be reported in two oral presentations, underscore the benefits of BRUKINSA® as first-line treatment for patients with chronic lymphocytic leukemia (CLL) Promising early phase data show the strength of the pipeline in treating multiple solid tumor…
The U.S. Bankruptcy Court of New Jersey approved CVS Pharmacy® bids on the prescription files of 625 Rite Aid pharmacies across 15 states in areas that CVS serves, as well 64 Rite Aid stores in Idaho, Oregon and Washington. The transaction…
Johnson & Johnson MedTech Launches SOUNDSTAR CRYSTAL™ Ultrasound Catheter in the U.S. to Enhance Cardiac Ablation Procedures May 2025 – Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, has announced the U.S. launch of the SOUNDSTAR CRYSTAL™…
Access to Obesity Medications Shouldn’t Be This Hard Recent changes in insurance coverage have forced thousands of Americans living with obesity into an impossible choice: stop taking a safe, effective medication recommended by their health care provider—or pay out of…
Eli Lilly’s Kisunla Receives Regulatory Approval in Australia for Early Alzheimer’s Treatment Eli Lilly and Company (NYSE: LLY) announced today that Australia’s Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (donanemab), an intravenous infusion therapy administered every four…
Aetna Better Health® of Illinois Invests $20.4 Million in Value-Based Care to Improve Health Outcomes in Underserved Communities Aetna Better Health® of Illinois, a CVS Health® company (NYSE: CVS), has distributed $20.4 million in value-based care incentive payments to several…
AstraZeneca Showcases Oncology Breakthroughs at ASCO 2025, Reinforcing Mission to Eliminate Cancer as a Cause of Death AstraZeneca will present new data from over 80 abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 –…
Roche Presents Positive ODAC Discussion on Columvi® Combination Therapy for Aggressive Lymphoma Basel, Switzerland – May 21, 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) held…
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data arising from two analyses from SEQUOIA-HCM, (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), and results from a real-world analysis related to…
FDA Under Makary Eyes New Pathway for Rare Disease Drugs Amid Debate Over Feasibility and Safety While the U.S. Food and Drug Administration (FDA) under new Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. may seem a far…
FDA and NIH Push Toward Replacing Animal Testing with AI and Human Organoids In a groundbreaking move, the FDA—under Commissioner Marty Makary—announced plans in April to significantly reduce animal testing requirements for monoclonal antibodies and other therapies. The agency aims…